Metal-based antitumour drugs in the post genomic era.

By P. Dyson, G. Sava. Dalton Transactions, 2006

685 citations recorded by the source corpus.

Subfields: Oncology, Organic Chemistry, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/cd82dfb7af11831fd48d9e87e585e19047ea02e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. P. Sadler

In Organic Chemistry

1. P. Sadler

In Radiology, Nuclear Medicine and Imaging

1. P. Sadler

Citations in the corpus

• Organometallic Anticancer Compounds (2010, background): “118 This discovery is of high practical interest as the removal of the primary tumor by surgery is frequently an efficient procedure while the treatment options for metastases are quite limited.(2)”
• ‘New Trends for Metal Complexes with Anticancer Activity’ (2008, background): “com and specifically aim at non-classical targets such as gene products and cellular transduction pathways [22].”
• Metal-Organic Frameworks as Potential Drug Carriers (2010, neutral): “Current therapeutics are limited by their nonspecific distribution throughout the body leading to high doses, rapid clearance, poor pharmacokinetics, and high side effects [1,2].”